Last updated: September 7, 2026
BEXSERO is GSK’s recombinant meningococcal group B vaccine, marketed as 4CMenB. Its commercial profile is driven by adolescent vaccination policy, outbreak response, public-health procurement, and private-market adoption rather than chronic treatment demand. GSK’s reported BEXSERO sales have expanded from a regional vaccine franchise into a product with more than £1 billion in annual revenue, supported by U.S. uptake, United Kingdom procurement, and broader international demand.
The main commercial risks are uneven national recommendations, low routine MenB vaccination coverage, procurement pricing, competition from Pfizer’s TRUMENBA, and the absence of a universal adolescent MenB program in the United States.
What is BEXSERO and how does it work?
BEXSERO is a multicomponent vaccine for preventing invasive disease caused by Neisseria meningitidis serogroup B. It contains recombinant antigens and outer-membrane-vesicle material designed to generate immune responses against diverse MenB strains.
In the United States, the FDA approved BEXSERO in 2015 for active immunization against invasive meningococcal disease caused by serogroup B in individuals 10 through 25 years of age. The product is administered as a two-dose series at least one month apart under the current U.S. label. The CDC recommends MenB vaccination through shared clinical decision-making for people ages 16 through 23, with a preferred age of 16 through 18, rather than universal routine vaccination for all adolescents. [1,2]
BEXSERO is also used in other jurisdictions for infants, children, adolescents, and adults under country-specific schedules. These broader age indications increase the addressable market but make demand dependent on local health policy and reimbursement.
How has BEXSERO revenue developed?
GSK does not always present BEXSERO revenue in identical formats across annual reports, and currency movements affect year-to-year comparisons. The product has nevertheless shown a clear upward trajectory.
| Fiscal year |
BEXSERO reported sales |
Primary commercial drivers |
| 2021 |
Approximately £0.7 billion |
U.K. infant program, U.S. demand, international tenders |
| 2022 |
Approximately £0.9 billion |
U.S. growth and recovery in vaccination activity |
| 2023 |
Approximately £1.0 billion |
Higher U.S. demand and international sales |
| 2024 |
More than £1.0 billion |
Continued U.S. growth, government procurement, broader geographic demand |
Sources: GSK annual reports and full-year results. [3-6]
The revenue trajectory is strategically important because BEXSERO has become one of GSK’s largest vaccine products, although it remains smaller than SHINGRIX. BEXSERO sales benefit from high unit value, repeat government procurement, and the potential for age-based recommendations to expand. The product does not have the same predictable annual demand profile as a universal childhood vaccine because MenB vaccination is not uniformly included in national immunization schedules.
What explains BEXSERO’s sales growth?
The principal growth factors are:
- U.S. adolescent and young-adult demand under shared clinical decision-making.
- National and regional public-health programs, including the U.K. infant program.
- University, military, and outbreak-related vaccination.
- Increased awareness of invasive meningococcal disease.
- Expansion of local approvals and reimbursement.
- GSK’s established manufacturing and distribution infrastructure.
The U.S. market is particularly important because private-sector vaccination can generate higher pricing than government tenders. The commercial ceiling remains constrained by the CDC’s shared-decision framework, which does not create a universal recommendation for all adolescents.
What is BEXSERO’s market size and commercial opportunity?
BEXSERO addresses several distinct markets rather than one uniform global segment.
United States
The U.S. market includes adolescents, college students, military personnel, people with certain medical conditions, laboratory workers, and individuals exposed to outbreaks. The CDC’s shared clinical decision-making recommendation gives clinicians and families discretion, which supports demand but produces lower coverage than a universal recommendation.
The U.S. opportunity is larger than current vaccinated-population data because many eligible adolescents remain unvaccinated. The limiting factor is conversion of eligibility into completed vaccination, not merely the size of the age cohort.
United Kingdom
The United Kingdom introduced MenB vaccination into the infant routine schedule in 2015, creating a stable institutional market. The U.K. program has provided BEXSERO with a recurring base of government-funded demand. Procurement prices are lower than private U.S. prices, but volume is more predictable.
Europe and other markets
Several countries recommend MenB vaccination for infants, adolescents, or high-risk groups. Others use targeted vaccination or make the product available without universal public reimbursement. Market performance therefore depends on tender wins, reimbursement policy, local epidemiology, and national budget priorities.
How does BEXSERO compare with TRUMENBA?
BEXSERO and TRUMENBA are the two principal licensed U.S. MenB vaccines.
| Attribute |
BEXSERO |
TRUMENBA |
| Manufacturer |
GSK |
Pfizer |
| Vaccine type |
Multicomponent recombinant protein plus OMV |
Recombinant factor H-binding protein |
| U.S. approval |
2015 |
2014 |
| U.S. age range |
10 through 25 years |
10 through 25 years |
| U.S. use |
Shared clinical decision-making and high-risk use |
Shared clinical decision-making and high-risk use |
| Schedule |
Two doses under current U.S. labeling |
Two- or three-dose schedules depending on indication and schedule |
| Key commercial strength |
Broad international use and established U.K. infant program |
Pfizer scale and competitive U.S. presence |
Neither product has a decisive U.S. policy advantage because the CDC does not recommend universal MenB vaccination for all adolescents. Product selection can depend on supply, contract pricing, physician preference, schedule, and institutional procurement.
BEXSERO has a more established international and infant-market position in some countries. TRUMENBA benefits from Pfizer’s commercial scale and its own established regulatory footprint. The competitive market is therefore shaped by procurement execution as much as by clinical differentiation.
What patents protect BEXSERO?
BEXSERO is protected by a layered intellectual-property estate covering antigens, combinations, vaccine compositions, manufacturing processes, and methods of preventing MenB disease. The relevant rights originate from research conducted by Chiron, Novartis, and related entities before GSK acquired the vaccine business.
The core technology includes:
- Factor H-binding protein, or fHbp.
- Neisserial adhesin A, or NadA.
- Neisserial heparin-binding antigen, or NHBA.
- Outer-membrane-vesicle components.
- Antigen combinations and adjuvant systems.
- Fermentation, purification, and formulation processes.
- Methods for inducing protection against diverse MenB strains.
No single patent expiration date defines BEXSERO’s commercial protection. Core platform patents generally expire earlier than later-filed formulation, manufacturing, or antigen-combination patents. The practical protection period therefore depends on the jurisdiction, claim scope, patent-term adjustments, supplementary protection certificates, and whether a later entrant can design around individual claims.
Is BEXSERO listed in the Orange Book?
The Orange Book is primarily used for FDA-approved small-molecule drug products and associated patent certifications. BEXSERO is a biologic vaccine licensed under the Public Health Service Act, so its principal regulatory reference is the FDA biologics framework rather than the conventional Orange Book Paragraph IV system.
The absence of a conventional Orange Book listing does not mean the product lacks patent protection. It means that a potential competitor would evaluate biologic licensing rules, patent litigation, manufacturing capability, and regulatory pathways rather than relying solely on a small-molecule ANDA strategy.
When does BEXSERO lose regulatory exclusivity?
BEXSERO received U.S. biologic approval in 2015. Under the Biologics Price Competition and Innovation Act, a reference biologic generally receives 12 years of reference-product exclusivity from first licensure, subject to statutory rules governing what constitutes the same product and how supplements are treated. On that framework, the principal U.S. reference-product exclusivity period runs to approximately 2027. [7]
Regulatory exclusivity is not the same as patent expiry. After the exclusivity period, a biosimilar applicant may pursue a 351(k) pathway if the product and evidence package satisfy FDA requirements. Approval would still require analytical comparability, clinical evidence appropriate to the product, manufacturing validation, and a commercially viable supply chain.
For a complex multicomponent vaccine, regulatory approval is a substantial barrier. A biosimilar or follow-on applicant would need to reproduce antigen identity, purity, potency, consistency, immunogenicity, and manufacturing controls. A conventional generic substitution pathway is not available.
What generic and biosimilar entry risks exist?
Near-term conventional generic entry risk is low. BEXSERO is a biologic vaccine with a complex manufacturing process, and there is no simple tablet-style ANDA route.
The principal future risks are:
- A follow-on biologic application after reference-product exclusivity.
- A competing vaccine with overlapping serogroup B coverage.
- A new MenB vaccine using different antigen technology.
- Government procurement substitution.
- Patent challenges to antigen, formulation, or manufacturing claims.
- Price competition in tender markets.
Biosimilar substitution may also be less automatic than substitution for many injectable medicines. State pharmacy laws, payer policies, public-health tenders, and product-specific interchangeability decisions will influence actual erosion.
Which companies are challenging BEXSERO?
The principal commercial challenger is Pfizer through TRUMENBA. No established U.S. biosimilar competitor has materially disrupted BEXSERO sales. The competitive threat is therefore product-level competition rather than a current patent-litigation-driven generic wave.
Patent litigation risk would most likely arise if a follow-on manufacturer sought to commercialize a MenB vaccine using protected antigen combinations, expression systems, formulation methods, or manufacturing processes. Publicly disclosed commercial competition does not establish that a specific company has cleared all BEXSERO-related patent barriers.
What patent litigation and settlement risks affect BEXSERO?
BEXSERO’s risk profile differs from that of a blockbuster small molecule. The relevant disputes would likely involve:
- Ownership of antigen and vaccine-platform patents.
- Patent-term adjustments and supplementary protection certificates.
- Process patents covering fermentation and purification.
- Patent scope for recombinant antigen combinations.
- Licensing rights from predecessor companies.
- Biosimilar approval timing under the BPCIA.
- Government procurement challenges.
A Paragraph IV challenge under an ANDA would not be the expected primary route because BEXSERO is a biologic vaccine. A BPCIA patent exchange and federal patent litigation could become relevant if a follow-on biologic applicant submits a 351(k) application.
How strong is the BEXSERO patent estate?
The patent estate is commercially meaningful but not the only barrier to entry. Its strength rests on four factors:
- The complexity of reproducing the multicomponent vaccine.
- Manufacturing know-how and validated production systems.
- Regulatory requirements for a highly characterized biologic.
- GSK’s ability to defend formulation, antigen, and process claims.
Patent strength is likely highest where claims cover specific antigen combinations, engineered proteins, or validated production methods. It is weaker where broad platform claims face prior-art, enablement, written-description, or obviousness challenges.
The practical barrier is therefore a combination of patents, regulatory exclusivity, manufacturing know-how, quality systems, and supply agreements.
What manufacturing and supply-chain barriers affect BEXSERO?
BEXSERO manufacturing requires controlled production of recombinant antigens and outer-membrane-vesicle material, followed by purification, combination, formulation, filling, and release testing. The process requires specialized facilities and extensive batch-consistency data.
Important barriers include:
- Limited capacity for complex vaccine production.
- Long validation timelines for new manufacturing sites.
- Control of antigen ratios and potency.
- Cold-chain distribution.
- Regulatory comparability after process changes.
- Dependence on specialized raw materials and quality testing.
- Capacity allocation during outbreaks or seasonal demand peaks.
These barriers reduce the probability that a patent expiry would produce immediate price collapse.
What is BEXSERO’s financial outlook?
BEXSERO should remain a material GSK vaccine franchise through the late 2020s. Growth depends on three variables: U.S. uptake, expansion of national MenB programs, and procurement volume outside the United States.
The upside case includes broader adolescent recommendations, increased college and institutional vaccination, and new government-funded programs. The base case is continued growth at a slower pace as the product matures. The downside case includes flat U.S. coverage, tender-price pressure, competitor gains, and post-exclusivity follow-on competition.
BEXSERO’s revenue exposure is meaningful for GSK but less concentrated than a single-product pharmaceutical company’s exposure because GSK has a diversified vaccine portfolio led by SHINGRIX, Arexvy, and other products.
Key Takeaways
- BEXSERO is GSK’s multicomponent MenB vaccine and a major global vaccine product.
- Annual sales have grown from roughly £0.7 billion in 2021 to more than £1 billion in recent reporting periods.
- U.S. demand is commercially important but constrained by shared clinical decision-making rather than universal adolescent vaccination.
- The principal competitor is Pfizer’s TRUMENBA.
- BEXSERO does not follow a conventional small-molecule Orange Book and Paragraph IV pathway.
- U.S. biologic reference-product exclusivity is expected to run to approximately 2027 under the 12-year BPCIA framework.
- Follow-on entry will be constrained by complex manufacturing, regulatory comparability, patents, and supply-chain requirements.
- The strongest commercial upside would come from broader national MenB recommendations and higher routine vaccination coverage.
FAQs About BEXSERO Market and Exclusivity
Is BEXSERO a biologic or a vaccine?
BEXSERO is both a vaccine and a biologic medicinal product. It is a multicomponent recombinant vaccine licensed by the FDA under the Public Health Service Act.
Is BEXSERO interchangeable with TRUMENBA?
No. BEXSERO and TRUMENBA are different MenB vaccines with different antigen compositions. They should not be treated as interchangeable products without applicable regulatory and clinical guidance.
Does BEXSERO have pediatric sales beyond adolescents?
Yes. In several countries, BEXSERO is used in infant and childhood programs. The U.K. infant program is one of the most important examples of publicly funded pediatric demand.
What would cause BEXSERO sales to decline?
The main risks are reduced government procurement, lower vaccination coverage, price pressure, loss of institutional contracts, competitor gains, and follow-on biologic entry after regulatory exclusivity.
Could BEXSERO become a universal adolescent vaccine in the United States?
That would require a change in U.S. public-health recommendations and payer implementation. Current CDC guidance uses shared clinical decision-making for adolescents and young adults rather than universal routine MenB vaccination.
References
- U.S. Food and Drug Administration. (2015). BEXSERO prescribing information.
- Centers for Disease Control and Prevention. (2024). Meningococcal vaccination: Who needs it and when.
- GSK plc. (2022). Annual report 2021.
- GSK plc. (2023). Annual report 2022.
- GSK plc. (2024). Annual report 2023.
- GSK plc. (2025). Annual report 2024.
- U.S. Food and Drug Administration. (2024). Biologics price competition and innovation act and reference product exclusivity.
